Rice University, University of Houston, and two other schools made this year's ranking of top grad schools. Photo via Rice.edu

Houston's top-tier universities have done it again. U.S. News and World Report has four Houston-area universities among the best grad schools in the state, with some departments landing among the top 100 in the country.

U.S. News publishes its annual national "Best Graduate Schools" rankings, which look at several programs including business, education, engineering, fine arts, health, and many others. For the 2024 report, the publication decided to withhold its rankings for engineering and medical schools. It also changed the methodology for ranking business schools by adding a new "salary indicator" based on a graduate's profession.

U.S. News also added new rankings for doctoral and master's programs in several medical fields for the first time in four years, or even longer in some cases. New specialty program rankings include audiology, occupational therapy, physical therapy, pharmacy, nurse midwifery, speech-language pathology, nurse anesthesia, and social work.

"Depending on the job or field, earning a graduate degree may lead to higher earnings, career advancement and specialized skill development," wrote Sarah Wood, a U.S. News Education reporter. "But with several types of degrees and hundreds of graduate schools, it can be difficult to narrow down the options."

Without further ado, here's how the local schools ranked:

Rice University's Jesse H. Jones Graduate School of Business maintained its position as No. 2 in Texas, but slipped from its former No. 24 spot in the 2023 report to No. 29 overall in the nation in 2024. Its entrepreneurship program tied for No. 8 in the U.S, while its part-time MBA program ranked No. 15 overall.

Houston's University of Texas Health Science Center earned the No. 3 spots in Texas for its masters and doctorate nursing programs, with the programs earning the No. 31 and No. 45 spots overall in the nation. The school ranked No. 25 nationally in the ranking of Best Public Health schools, and No. 36 for its nursing-anesthesia program.

Prairie View A&M University's Northwest Houston Center ranked No. 5 in Texas and No. 117 in the nation for its master's nursing program. Its Doctor of Nursing Practice program ranked No. 8 statewide, and No. 139 nationally.

The University of Houston moved up one spot to claim No. 4 spot in Texas for its graduate education program, and improved by seven spots to claim No. 63 nationally. Its graduate business school also performed better than last year to claim No. 56 in the nation, according to the report. The University of Houston Law Center is the fifth best in Texas, and 68th best in the U.S. Most notably, its health care law program earned top nods for being the seventh best in the country.

Among the new specialty program rankings, UH's pharmacy school ranked No. 41 nationally, while the speech-language pathology program earned No. 44 overall. The graduate social work and public affairs programs ranked No. 67 and No. 76, respectively, in the nation.

The full list of best graduate schools can be found on usnews.com.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”

Houston startup raises $6M to scale home-based healthcare platform

fresh funding

As healthcare systems race to expand care beyond hospitals and into the home, investors are placing bigger bets on the infrastructure needed to make that shift possible.

This month, Rosarium Health announced it has raised $6 million in seed funding led by Kalos Ventures, with participation from ResilienceVC, Rock Health Capital, Symphonic Capital, Black Tech Nations Ventures and others.

The investment will help the Houston-based startup continue to build its platform, which features a national network of 800-plus clinicians and 3,000-plus contractors to coordinate home accessibility upgrades and modifications for seniors and people living with disabilities.

For founder and CEO Cameron Carter, the company’s mission grew out of firsthand caregiving experiences.

“From my own personal caregiving experiences, I realized that the benefits exist on paper, but not in reality,” Carter said in a news release. “Families are being left to figure out the paperwork and installations all on their own, which shouldn’t be how this works.”

While Medicare Advantage and Medicaid plans have expanded coverage for home-based services and accessibility modifications, the logistics behind delivering those services often remain fragmented.

Rosarium’s platform coordinates the entire process, from clinical assessments and referrals to contractor management, documentation, reimbursement and installation.

“A clinician can document that a home isn’t safe and a plan can approve a benefit, but there’s no one that’s responsible for making sure the work actually gets done,” Carter says. “We built the missing piece.”

The company was founded in 2021 as Rose Health and was a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. It has scaled quickly, building a network of more than 800 clinicians and 3,000 contractors across 34 states.

Rosarium is currently in-network for 1.2 million Medicare and Medicaid lives, with projected coverage expected to reach nearly 4 million by the end of the year, according to the release.

“We’re excited to back Cameron because he and the team at Rosarium are building the infrastructure healthcare needs right now to make the home a safe and comfortable place of care,” Kate Ballinger, investor at Kalos Ventures, added in the release.

As part of the recent investment, Ballinger will join Rosarium’s board of directors.

With eyes on the future, Rosarium plans to grow its partnerships with Medicaid and Medicare Advantage plans, including CalViva and Community Health Plan of Imperial Valley, strengthening its presence in California while expanding access to underserved communities.

Additionally, Carter predicts that home-based healthcare will be part of a broader transformation happening across the industry.

“There’s a growing recognition that health outcomes are shaped by what happens in the home,” he said in the release. “The future of healthcare isn’t just treating people after something goes wrong. It’s creating environments that help prevent those problems in the first place.”